{"entity":{"id":"aleix-prat","kind":"person","name":"Aleix Prat","aka":[],"tldr":"Translational oncologist who built genomic tests (HER2DX) to decide which HER2-positive patients can skip chemotherapy.","summary":"Aleix Prat developed the HER2DX genomic assay and led PAM50-based analyses across breast cancer trials, and is a principal investigator of PHERGain, which uses PET response to omit chemotherapy in HER2-positive early disease. He directs medical oncology at Hospital Clínic and the SOLTI cooperative group, focusing on biology-guided de-escalation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prat%20A%5BAuthor%5D%20breast%20PAM50%20HER2DX"}],"tags":["breast","genomics","de-escalation"],"related":[],"cancers":["breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":["rna-seq","fdg-pet"],"targets":[],"drugs":[],"companies":["solti"],"institutions":["hospital-clinic-barcelona"],"pathways":[],"terms":[],"trials":["phergain"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["the-breast"],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Hospital Clínic de Barcelona; Scientific Director, SOLTI","institutionId":"hospital-clinic-barcelona","specialisms":["Breast cancer genomics","HER2-positive de-escalation","PAM50 and HER2DX","Neoadjuvant trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prat%20A%5BAuthor%5D%20breast%20PAM50%20HER2DX"}],"papers":[{"title":"Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00122-4"},{"title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","journal":"The Breast","year":2015,"doi":"10.1016/j.breast.2015.07.008"}],"orcid":"0000-0003-2377-540X"},"route":"/people/aleix-prat/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"company":[{"id":"solti","kind":"company","name":"SOLTI Cancer Research Group","route":"/companies/solti/"}],"institution":[{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/"}],"trial":[{"id":"phergain","kind":"trial","name":"PHERGain","route":"/trials/phergain/"}],"journal":[{"id":"the-breast","kind":"journal","name":"The Breast","route":"/journals/the-breast/"}],"paper":[{"id":"paper-schettini-her2-low-features-npj-breast-cancer-2021","kind":"paper","name":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","route":"/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/"}]}}